Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine and Sulindac in Familial Adenomatous Polyposis
NCT01483144Phase 3Completed
- Start
- Oct 2013
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of eflornithine in familial adenomatous polyposis (FAP). Started Oct 2013; status: completed.
02
Drugs
eflornithine
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT01483144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01483144.